SavedAdd your journal

Journals / Ege Klinikleri Tıp Dergisi / 2021 / Cilt: 59 - Sayı: 3

İnvestigation of Left Ventricular Systolic and Diastolic Functions Before and After Levosimendan Administration in Patients with Heart Failure

Kalp Yetmezliği Olan Hastalarda Levosimendan Verilmesi Öncesi ve Sonrası Sol Ventrikül Sistolik ve Diyastolik Fonksiyonlarının Değerlendirilmesinin Araştırılması

Zeynep YAPAN EMREN
Ferhat YURDAM
Oktay ŞENÖZ
Pages
1–5
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Levosimendan treatment has an acute favoruble effect in ejection fraction and diyastolic mitral inflow parameters that showed ventricle overload

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: we aimed to investigate effect of levosimendan treatment on left ventricle systolic and diastolic parameters with transthoracic echocardiography in patients with heart failure Method: Patients over 18 years old with lower than %35 of ejection fraction and New York Heart Association (NYHA) class III-IV were included.
📊
Key Findings & Data:Results: With levosimendan treatment; E/A ratio(2,25±0,76 vs 1,67±0,75 , p:0,03 ) and E/E’ ratio (23,03±13,60 vs 15,96±8,43 , p:0,01) decreased significantly.
💡
Conclusion & Impact:Conclusion: Levosimendan treatment has an acute favoruble effect in ejection fraction and diyastolic mitral inflow parameters that showed ventricle overload
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: we aimed to investigate effect of levosimendan treatment on left ventricle systolic and diastolic parameters with transthoracic echocardiography in patients with heart failure Method: Patients over 18 years old with lower than %35 of ejection fraction and New York Heart Association (NYHA) class III-IV were included. Left ventricle systolic and diastolic parameters before and after levosimendan treatment were compared. Approval was obtained from the local ethics committee of Celal Bayar University Medical Faculty for our study. Results: With levosimendan treatment; E/A ratio(2,25±0,76 vs 1,67±0,75 , p:0,03 ) and E/E’ ratio (23,03±13,60 vs 15,96±8,43 , p:0,01) decreased significantly. Furthermore there was an increase in ejection fraction(20,60±5,65 vs 27,00±7,11 , p:0,01) and A velocity( 0,45±0,14 vs 0,61±0,30 , p:0,03). Conclusion: Levosimendan treatment has an acute favoruble effect in ejection fraction and diyastolic mitral inflow parameters that showed ventricle overload

Özet

Amaç: Kalp yetmezliği hastalarında Levosimendan tedavisinin, sol ventrikülün sistolik ve diyastolik parametreleri üzerine etkisinin transtorasik ekokardiyografi ile araştırılması amaçlandı. Yöntem: 18 yaş üstü, sol ventrikül ejeksiyon fraksiyonu (LVEF) %35’den düşük, semptom sınıfı New York Kalp Cemiyeti (NYHA) sınıf III-IV olan, Levosimendan tedavisi almış 15 hasta dahil edildi. Tüm hastaların sol ventrikül sistolik ve diyastolik parametreleri levosimendan tedavisinin öncesinde ve sonrasında değerlendirildi. Çalışmamız için Celal Bayar Üniversitesi Tıp fakültesi Yerel Etik Kurulu Onayı alındı. Bulgular: Levosimendan tedavisi ile; E/A oranı (2,25±0,76 vs 1,67±0,75 , p:0,03), E/e’ oranlarında (23,03±13,60 vs 15,96±8,43 , p:0,01) ve A velosite değeri( 0,45±0,14 vs 0,61±0,30 , p:0,03) anlamlı azalma izlendi. Buna ek olarak sol ventrikül ejeksiyon fraksiyonunda(20,60±5,65 vs 27,00±7,11 , p:0,01) anlamlı artış izlenmiştir. Sonuç: Levosimendan tedavisi ejeksiyon fraksiyonu ve diyastolik mitral dolum parametrelerinde olumlu akut etkiye sahiptir.

🔖

Cite This Article

EMREN, Z. Y., YURDAM, F., ŞENÖZ, O. (2022). İnvestigation of Left Ventricular Systolic and Diastolic Functions Before and After Levosimendan Administration in Patients with Heart Failure. Ege Klinikleri Tıp Dergisi, Cilt: 59 - Sayı: 3, 1–5. https://ajindex.com/articles/495575

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. American Heart Association. Heart disease and stroke statics – 2007 update. Dallas, Texas: american heart association; 2007; 1-43
  2. Cavusoglu Y. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompanseted heart failure. Expert Opin Pharmacother 2007; 8: 665-77
  3. Aras D, Topaloğlu S, Korkmaz Ş. Dekompanse kalp yetersizliği tedavisinde yeni bir inotropik ajan: Levosimendan. Türk Kardiyoloji Dern Arş 2007; 35: 48- 56 4. Gruhn N, Nielsen-Kudsk JE, Theilgaard S et al. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol 1998; 31: 741-9
  4. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed Little, Brown & Co; Boston, Mass: 1994. pp. 253–256
  5. Dernellis J, Panaretou M, Effects of levosimendan on restrictive left ventricular filling in severe heart failure. Acombined hemodinamyyc and Dopler echocardiography study. CHEST 2005; 128: 2633-2639
  6. Kiris T, Avcı E,. Short-termeffects of levosimendan on strain/strain rate markers in patients with nonischemic dilate cardiomyopthy. J Clin Ultrasound. 2018 Oct;46(8):527-532
  7. M. Packer, W. Colucci, L. Fisher, BM Massie, JR Teerlink, J Young, RJ Padley, R Thakkar, L Delgado – Herrera, J Salon, C Garratt, B Huang, T Sarapohja; REVIVE Heart Failure Study Group. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013 Apr; 1(2): 103-111
  8. Altenberger J, Parissis JT, Costard-Jaeckle A, Winter A, Ebner C, Karavidas A, Sihorsch K, Avgeropoulou E, Weber T, Dimopoulos L, Ulmer H, Poelzl G. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial. Eur J Heart Fail 2014 Aug; 16 (8):898-906
  9. Mavrogeni S, Giamouzis G, Papadopoulou E, et al. A 6-month followup of intermittant levosimendan administration effect on systolic function, specific actvity questionnaire, and arrhythmia n advanced heart failure. J Card Fail. 2007; 13: 556-559.